Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
3.00
Dollar change
-0.05
Percentage change
-1.64
%
Index- P/E- EPS (ttm)-4.02 Insider Own40.12% Shs Outstand8.27M Perf Week0.00%
Market Cap23.73M Forward P/E- EPS next Y-3.27 Insider Trans-0.01% Shs Float4.74M Perf Month6.38%
Income-32.82M PEG- EPS next Q-1.14 Inst Own25.90% Short Float6.27% Perf Quarter-0.66%
Sales1.74M P/S13.64 EPS this Y-9.11% Inst Trans7.91% Short Ratio12.80 Perf Half Y8.86%
Book/sh4.48 P/B0.67 EPS next Y19.27% ROA-51.71% Short Interest0.30M Perf Year-12.79%
Cash/sh5.40 P/C0.56 EPS next 5Y15.20% ROE-63.61% 52W Range2.63 - 4.55 Perf YTD-5.66%
Dividend Est.- P/FCF- EPS past 5Y29.09% ROI-78.84% 52W High-34.07% Beta0.67
Dividend TTM- Quick Ratio7.76 Sales past 5Y124.77% Gross Margin96.49% 52W Low14.07% ATR (14)0.15
Dividend Ex-Date- Current Ratio7.76 EPS Y/Y TTM-18.31% Oper. Margin-2040.59% RSI (14)49.15 Volatility4.25% 4.91%
Employees32 Debt/Eq0.18 Sales Y/Y TTM41.10% Profit Margin-1889.69% Recom1.00 Target Price22.50
Option/ShortNo / Yes LT Debt/Eq0.17 EPS Q/Q-20.35% Payout- Rel Volume0.49 Prev Close3.05
Sales Surprise-96.89% EPS Surprise9.41% Sales Q/Q-98.59% EarningsMar 07 AMC Avg Volume23.22K Price3.00
SMA20-1.02% SMA50-0.40% SMA200-8.65% Trades Volume11,377 Change-1.64%
Date Action Analyst Rating Change Price Target Change
Mar-11-21Upgrade Stifel Hold → Buy $4 → $24
Dec-03-20Initiated Cantor Fitzgerald Buy $32
Aug-26-20Initiated Piper Sandler Overweight $26
Aug-17-20Resumed ROTH Capital Buy $51
Aug-04-20Initiated H.C. Wainwright Buy $33
Feb-26-24 09:00AM
Feb-05-24 04:05PM
Jan-04-24 04:05PM
Nov-21-23 04:15PM
Nov-20-23 04:05PM
04:35PM Loading…
Nov-07-23 04:35PM
04:01PM
Sep-26-23 09:00AM
Sep-14-23 08:00AM
Sep-07-23 04:34PM
Aug-22-23 09:00AM
Aug-09-23 04:01PM
Jul-26-23 09:00AM
Jul-12-23 08:00AM
Jun-28-23 04:01PM
09:00AM Loading…
Jun-21-23 09:00AM
May-31-23 08:00AM
May-25-23 08:00AM
May-22-23 09:00AM
May-08-23 08:00AM
May-03-23 04:05PM
Apr-27-23 09:00AM
Apr-19-23 09:00AM
Mar-09-23 04:05PM
Mar-05-23 02:00PM
Mar-01-23 04:05PM
Feb-28-23 04:05PM
Feb-15-23 04:05PM
Jan-03-23 09:00AM
Dec-12-22 07:30AM
04:05PM Loading…
Nov-29-22 04:05PM
Nov-22-22 04:05PM
Nov-14-22 06:10AM
06:00AM
Sep-26-22 04:05PM
Aug-31-22 09:00AM
Aug-16-22 07:30AM
Aug-09-22 04:01PM
Jul-27-22 04:05PM
Jul-24-22 08:27AM
Jul-20-22 08:32PM
May-16-22 04:05PM
May-10-22 04:01PM
May-06-22 10:25AM
May-05-22 09:00AM
Apr-26-22 09:00AM
Apr-11-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 04:01PM
09:00AM
Feb-23-22 09:00AM
Feb-14-22 12:05PM
Jan-05-22 09:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-08-21 09:38AM
Nov-24-21 10:00AM
Nov-15-21 11:14AM
Nov-10-21 05:06PM
Nov-08-21 10:42AM
Nov-03-21 04:01PM
Oct-21-21 04:05PM
Sep-02-21 08:00AM
Aug-16-21 09:58AM
Aug-05-21 08:00AM
Aug-03-21 08:00AM
Aug-02-21 08:00AM
Jul-26-21 04:18PM
Jul-22-21 08:00AM
Jul-20-21 04:01PM
Jun-28-21 08:00AM
May-19-21 09:00AM
May-13-21 09:00AM
May-05-21 04:01PM
02:30PM
Apr-28-21 09:00AM
Apr-27-21 08:00AM
Apr-20-21 04:05PM
Apr-14-21 04:05PM
Mar-20-21 11:00AM
Mar-11-21 04:05PM
Mar-09-21 04:05PM
01:30PM
Mar-04-21 09:00AM
Mar-02-21 04:05PM
12:30PM
Feb-22-21 04:15PM
Feb-16-21 04:01PM
Dec-18-20 09:00AM
Dec-16-20 02:19AM
Nov-30-20 05:35PM
Nov-23-20 07:43PM
Nov-10-20 04:01PM
02:30PM
Nov-03-20 12:30PM
Oct-29-20 09:00AM
Oct-27-20 04:01PM
Aug-27-20 09:00AM
Aug-13-20 04:01PM
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKew John C.Chief Scientific OfficerFeb 06Sale3.034381,32818,403Feb 07 05:22 PM
McKew John C.Chief Scientific OfficerAug 02Sale3.213,40710,91918,707Aug 03 04:58 PM
McKew John C.Chief Scientific OfficerApr 04Sale3.272,2147,24023,207Apr 04 05:22 PM